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Protection against TNF-Induced Lethal Shock
by Soluble Guanylate Cyclase Inhibition Requires
Functional Inducible Nitric Oxide Synthase
Nitric oxide (NO) is a very potent vasodilator generated
by a family of enzymes called NO synthases (NOS). At
least three different isoforms have been identified in
mammalian cells: two constitutive isoenzymes desig-
nated endothelial (e) and neuronal (n) NOS, activated
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Whereas in most studies systemic blood pressure was
successfully restored (Hock et al., 1997; Wray et al.,Hypotension and shock observed in sepsis, SIRS, and
1998), peripheral organ dysfunction was neverthelesstumor necrosis factor (TNF) or cytokine-based cancer
not or only partially attenuated (Thiemermann et al.,treatment are the consequence of excessive nitric ox-
1995; Gundersen et al., 1997; Wray et al., 1998). There-ide (NO) production and subsequent soluble guanylate
fore, we decided to look for selectivity among the effectscyclase (sGC)-mediated vascular smooth muscle re-
rather than the production of NO. One of the main ni-laxation. We demonstrate here that, while NO synthase
trosation targets of NO is the heme-iron present in(NOS) inhibitors exacerbated toxicity, inhibitors of sGC
soluble guanylate cyclase (sGC), thereby activating the
activation protected against TNF-induced lethality, enzyme resulting in cGMP accumulation and cGMP-
bradycardia, and hypotension. Importantly, sGC inhi- dependent cardiovascular changes such as vascular re-
bition did not interfere with the antitumor activity of laxation, myocardial depression, and the inhibition of
TNF. Using NOS inhibitors or iNOS-deficient animals, platelet aggregation and adhesion (Waldman and Murad,
we furthermore observed that no protection against 1987; Wolkow, 1998).
TNF toxicity could be obtained in the absence of NO. Considering the cGMP-dependent nature of the NO-
These data imply that iNOS- (and not eNOS-) derived mediated cardiovascular effects, we decided to aim for
NO is an endogenous protective molecule indispens- the selective inhibition of cGMP-mediated activities us-
able to survive a TNF challenge and exerting this bene- ing methylene blue (MB), a vital stain generally recog-
nized as an inhibitor of sGC activation both in vitro andficial effect via sGC-independent mechanisms.
in vivo (Gruetter et al., 1981; Murad, 1986) and described
to reverse hypotension in septic shock patients (Schnei-Introduction
der et al., 1992; Preiser et al., 1995; Driscoll et al., 1996;
Andresen et al., 1998), in anesthetized endotoxemicIn the course of the last decade, tumor necrosis factor
animals (Keaney et al., 1994; Paya et al., 1993), and in(TNF) has been attributed many diverse biological ac-
fecal peritonitis-induced shock (Galili et al., 1997), ortions in both immunological, physiological, and patho-
hypotension elicited by mere infusion of NO donors inphysiological processes. Originally this pleiotropic cyto-
conscious rats (Salvemini et al., 1996). In view of its well-kine was identified as a pivotal systemic mediator of
documented potential to restore blood pressure, we de-endotoxemic shock and tumor regression (Fiers, 1995).
cided to evaluate MB for its use in the treatment of TNF-The remarkable antitumor potential has been success-
induced shock.fully exploited in locoregional treatment (Lejeune et al.,
We here present evidence for MB to prevent lethality,1998) for which TNF was recently registrated as an anti-
cGMP accumulation, bradycardia, and hypotension incancer drug, but its systemic use is still severely ham-
TNF-induced shock. The detrimental role of sGC waspered by its shock-inducing properties. During clinical
further documented using another inhibitor of sGC acti-trials, hypotension was characterized as the dose-lim-
vation (LY83583) to protect or a cGMP phosphodiester-iting factor of TNF toxicity (Alexander and Rosenberg,
ase inhibitor (zaprinast) to reverse MB protection. How-1991).
ever, when the induction of NO was totally blocked via
additional treatment with NOS inhibitors, MB protection§ To whom correspondence should be addressed (e-mail: anje@
dmb.rug.ac.be [A. C.], peterb@dmb.rug.ac.be [P. B.]). was completely abolished. In addition, iNOS- (but not
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Figure 1. Lethality Induced by TNF in the
Four Models
The total number of mice used is indicated
above each bar. All mice were i.v. challenged
with a 100% lethal dose of mTNF or hTNF,
determined with the same lot of TNF and mice
before the start of each individual experi-
ment. Open bars represent control mice pre-
treated with glucose (six mice for each model)
or PBS (the numbers indicated above the
open bar minus six). Cross-hatched bars are
mice that received 100 mg/kg L-NMMA,
L-NAME, or L-NIO either 2 hr or 30 min before,
together, or 5, 30, or 90 min after TNF. Inde-
pendent of the NOS inhibitor used or the time
point of its administration, mice could never
be protected. Closed bars represent mice
pretreated with MB at the time indicated be-
low the bars. Lethality was scored up to 7
days after TNF challenge. Generally, various
treatment groups were compared in one sin-
gle experiment using five to seven mice per
group. The results shown for models I, II, and
III represent the combination of up to five
independent experiments. Data for model IV
come from one single experiment.
eNOS-) deficient mice could never be significantly pro- activation, mice were protected very efficiently against
TNF-induced mortality in all four models (Figure 1).tected. We therefore conclude a bivalent role for NO in
TNF-induced toxicity: on the one hand mediating brady- Given the significant protection by MB, we next deter-
mined whether another inhibitor of sGC activation,cardia, hypotension, and subsequent shock via sGC
activation; on the other hand exerting a protective and LY83583 (Malta et al., 1988), had a similar effect against
mTNF-induced mortality. As plotted in Figure 2, LY83583cGMP-independent function, essential to survive. Con-
trary to the general assumption, the source for this pro- proved as capable as MB to protect. To further substan-
tiate the involvement of sGC-induced cGMP accumula-tective NO is iNOS and not eNOS, prompting us to ques-
tion the feasibility of selective iNOS inhibition as a tion in TNF lethality, MB pretreatment was combined
with multiple injections of zaprinast, a specific inhibitorstrategy to provide protection against TNF-induced or
-mediated diseases. of type V cGMP phosphodiesterase increasing cGMP
concentrations (data not shown). Zaprinast was injected
i.v. four times (together with, as well as 2, 5, and 8 hrResults
after mTNF), a treatment not lethal as such but very
efficient to abrogate MB protection (data not shown).MB and LY83583, but Not NOS Inhibitors, Protect
against TNF-Induced Lethality
Effect of MB on TNF-Induced cGMP Production,To investigate the role of NO and sGC in TNF-induced
Bradycardia, and Hypotensionshock, we performed experiments in four different le-
The experiments using MB, LY83583, and zaprinast indi-thality models in mice. In model I, nonsensitized mice
cated that sGC is a pivotal detrimental mediator of TNF-are i.v. challenged with a 100% lethal dose of mouse
induced lethality. To assure that MB is actually blocking(m) TNF, typically ranging from 20 to 30 mg. In the other
three models, human (h) TNF, which is normally not
lethal in healthy mice except at extremely high doses
(LD50 < 500 mg), is injected in sensitized mice. Mice are
sensitized by the presence of an i.m. LLC tumor (model
II), a BCG infection (model III), or repeated IL-12 injec-
tions (model IV). Sensitization models were described
in detail before (Cauwels et al., 1995, 1996). Essentially,
model III and IV may be regarded molecularly equivalent
since BCG sensitization can be abrogated by anti-IL-12
treatment and both models were shown to depend on
endogenous IFNg for sensitization (Cauwels et al., 1995,
1996).
Treatment of mice with different NOS inhibitors
(L-NAME, L-NMMA, or L-NIO) at various time points (be-
fore, together, or after TNF challenge) could not protect Figure 2. Protection by LY83583 as Compared to MB in Model I
in any of the models used (Figure 1). Treatment with NOS
All mice received a lethal dose of mTNF (25 mg), combined with
inhibitors actually exacerbated rather than ameliorated 25% DMSO as a control (open bar), MB at 22 hr (closed bar), or
TNF toxicity, in a sense that LD100-challenged mice died LY83583 (diluted in 25% DMSO) at the time indicated beneath the
earlier and an LD25 TNF dose would become 100% lethal hatched bars. Each bar represents a group of six mice. All mice were
in combination with L-NAME (data not shown). However, treated in the same experiment. Extra independent experiments
(dose±response) revealed similar results.when we used the harmless stain MB to block sGC
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(Figure 4A) but efficiently prevented by pretreatment
with MB (Figure 4B). MAP data after TNF challenge
showed an immediate transient drop in blood pressure,
followed by the delayed hypotension. Nonlethal TNF
doses caused minor hypotension (data not shown),
whereas a lethal TNF injection resulted in severe hypo-
tension (.40 mmHg MAP reduction) within the 10 hr
observation period in 4/7 animals (Figure 4C). When
mice were pretreated with MB, this severe hypotension
was never observed (Figure 4D). All mice pretreated with
Figure 3. cGMP Accumulation in Plasma and Kidney Homogenates MB survived the normally lethal TNF challenge, while all
Mice were injected with PBS (open bars), a lethal dose of 25 mg glucose-pretreated animals died within 20 hr after TNF
mTNF (closed bars), or MB 1 mTNF (hatched bars). Plasma (A) and injection. Overall, MAP and HR in MB 1 mTNF treated
kidneys (B) were collected 5 hr after mTNF challenge. Plotted are mice did not differ significantly from control mice treated
the means 6 SEM of eight or nine mice coming from three separate with MB alone (data not shown).
experiments. ***p , 0.001 (one-way ANOVA Bonferroni test).
Evidence for a Protective Role of NO
in TNF-Induced ShocksGC activation, cGMP was measured in plasma and
kidney homogenates. Mice showed increased cGMP To determine why sGC but not NOS inhibition can pro-
tect mice from a lethal TNF challenge (Figure 1), MBconcentrations peaking about 5 hr after mTNF injection,
and this increase was downmodulated by MB pretreat- and L-NAME treatments were combined. MB protection
was totally abrogated by L-NAME in models I and II,ment (Figure 3).
In the cardiovascular system, NO-induced cGMP ac- where the L-NAME injection was capable of reducing
serum NO levels to below basal values (Figure 5). Incumulation in shock accounts for the relaxation of vas-
cular smooth muscle cells and myocytes, causing vaso- models III and IV, however, L-NAME could not com-
pletely eliminate the systemic presence of NO (not evendilatation and myocardial depression, respectively. To
evaluate the effect of MB on TNF-induced hemodynamic when L-NAME was injected twice at a 5-fold higher
dose; data not shown) and MB could still provide 100%changes, mean arterial blood pressure (MAP) and heart
rate (HR) were monitored continuously in free-moving protection even in combination with L-NAME treatment
(Figure 5). It should be noted that in these latter modelsconscious mice. Both HR and MAP dropped drastically
within 5 min of MB pretreatment, but recovered fast and the mere presence of a BCG infection or IL-12 sensitiza-
tion caused a substantial presence of NOx2 in circulationwere back to seminormal levels at the time of mTNF
injection 2 hr later (Figures 4B and 4D). TNF lethality before TNF was administered (Figure 5, open bars).
Taken together, these data imply that MB can no longercould invariably be predicted by a severe drop in HR
starting only a couple of hours after the TNF challenge protect against TNF-induced lethality if NO is completely
Figure 4. Individual Heart Rate Changes and MAP Changes
Heart rate (HR) (A and B) and MAP (C and D) changes are plotted as compared to baseline values at time 0 (typically varying between 650
and 750 beats per minute and 95 to 115 mmHg), immediately before the i.v. injection with 200 ml glucose as a vehicle (A and C) or 15 mg/kg
MB (B and D). A lethal dose of 20 mg mTNF, or endotoxin-free PBS as a control, was administered i.v. 2 hr later. Mice were monitored
continuously for 10±12 hr. All glucose-pretreated animals died within 20 hr after TNF challenge, whereas all MB-pretreated mice survived the
otherwise lethal mTNF challenge.
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Figure 5. NOx2 Determination as a Measure
for NO Release
The four different lethality models (I, II, III, and
IV) were used to measure NOx2 (NO22 1 NO32)
in serum obtained from mice i.v. injected with
PBS (controls, open bars), TNF (closed bars),
MB 1 TNF (hatched bars), or MB 1 TNF 1
L-NAME (cross-hatched bars). MB was given
2 hr before TNF, L-NAME 5 min afterward.
Plotted are means 6 SEM from at least six
mice. *** p , 0.001, **p , 0.01, *p , 0.05
(one-way ANOVA Bonferroni test). Numbers
underneath the bars represent the percent
lethality in the respective treatment groups
and models.
absent from the circulation, hinting toward the existence but not in iNOS-deficient (Figure 6B), animals. Survival
studies learned that eNOS-deficient mice behaved ex-of an indispensable protective role for NO in TNF toxicity.
actly like wild-type mice. In model I, MB protected com-
pletely against mTNF lethality and protection was abro-Identification of iNOS as the Source
gated by the extra treatment with L-NAME (Figure 6C),of the Protective NO
while, in model III, MB protection against TNF lethalityConsidering the presumed protective role of NO in TNF
could not be reversed by L-NAME (Figure 6D). In con-toxicity, we examined the effect of MB and L-NAME in
trast to the results in the eNOS-deficient animals, iNOS-eNOS- and iNOS-deficient mice. NO was clearly induced
following mTNF challenge in eNOS-deficient (Figure 6A), deficient mice could not significantly be protected by
Figure 6. NOx2 Measurement and Lethality of
TNF in C57Bl/6 and eNOS- and iNOS-Defi-
cient Mice
(A and B) To determine inducibility of NO, a
lethal dose of 20 mg mTNF was i.v. injected
in C57Bl/6 mice ([A and B], closed circle) or
in eNOS-deficient mice ([A], open circle) or
iNOS-deficient mice ([B], closed triangle). (A)
and (B) represent separate experiments. Plot-
ted are means 6 SEM from groups of four to
six mice. ***p , 0.001, **p , 0.01 (one-way
ANOVA Bonferroni test) comparing values of
C57Bl/6 with NOS-deficient mice. When not
indicated, NOx2 levels were not statistically
significant between wild-type or knockout
animals.
(C and D) Mortality studies were performed
in models I ([C], mTNF lethality) and III ([D],
hTNF lethality in BCG-primed animals), where
bars represent percent lethality after i.v. in-
jection with PBS (open bars), TNF (closed
bars), MB 1 TNF (hatched bars), or MB 1
TNF 1 L-NAME (cross-hatched bars) in either
C57Bl/6 mice as wild-type (WT) controls or
eNOS-deficient or iNOS-deficient mice as in-
dicated below the respective groups of bars.
MB was given 2 hr before TNF, L-NAME 5
min afterward. Each bar represents a group
of 6±12 mice.
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Figure 7. Effect of MB Pretreatment on
Treatment of a B16BL6 Tumor with mTNF and
mIFNg as Described in the Experimental Pro-
cedures
Tumor volume (A) and survival (B) are plotted
as a function of time (days after tumor in-
oculation). Each treatment group consisted
of five animals. Daily antitumor treatment
(arrows) was started on day 10 with PBS
(open circle) or mTNF 1 mIFNg (closed circle,
triangle, inverted triangle). Every second (tri-
angle) or third (inverted triangle) day, 15 mg/
kg MB was injected 2 hr before mTNF 1
mIFNg treatment. **p , 0.01 (logrank test), as
compared to mTNF 1 mIFNg without MB
pretreatment (closed circle). In total, four independent experiments were performed using either 7.5, 10, or 15 mg/kg MB (in each individual
experiment used daily, every other day, or every third day). Results from some of the other experiments are described in the Results.
MB pretreatment in model I (Figure 6C) and not at all in tumor and 100% survival of the tumor-free mice (data
model III (Figure 6D). In addition, treatment with LY83583 not shown). Hence, we conclude that MB pretreatment
could not protect iNOS-deficient mice against TNF mor- impairs toxicity but not the antitumor potential of TNF,
tality (data not shown). These results clearly prove that allowing a complete cure of tumor-bearing mice.
in the absence of iNOS MB or LY83583 fails to protect
against TNF lethality, implicating iNOS as the source of
protective NO in TNF toxicity. Discussion
MB Prevents Systemic Toxicity but Not the Antitumor In addition to the detrimental role of NO in shock-like
Activity of TNF diseases, described in a plethora of reports during the
TNF is a very potent antitumor agent, but its systemic last decade, studies in animal models and clinical trials
use is seriously limited due to its shock-inducing proper- using NOS inhibitors suggest a beneficial role for NO as
ties. We have identified MB as a drug to prevent TNF- well. The disappointing results obtained with nonselec-
induced systemic toxicity and lethality. However, to be tive NOS inhibitors resulted in a quest for selective iNOS
considered therapeutically valuable, we needed to verify inhibitors, based upon the involvement of eNOS in the
whether MB interferes with the antitumor activity of TNF normal regulation of vascular tone and the upregulation
or not. For this purpose, we tested the effect of MB of iNOS in inflammatory conditions. Still, discrepant re-
pretreatment on the antitumor efficacy of mTNF and sults have been obtained using these iNOS-selective
mIFNg against a syngeneic murine B16BL6 melanoma inhibitors in various endotoxic shock models. For that
tumor. As described previously (Brouckaert et al., 1986), reason, we started to question the advantage of selec-
daily treatment of tumor-bearing mice with a combina- tive iNOS inhibitors as therapeutic agents and decided
tion of 10 mg mTNF and 5000 IU mIFNg caused a com- to aim for the selective inhibition of NO-mediated effects
plete regression of the tumor (Figure 7A) but proved rather than NO production. So far, sGC is the only con-
toxic resulting in 100% lethality by the end of the treat-
clusively proven receptor for NO and is involved in many
ment (Figure 7B). It should be noted that in contrast to
NO-mediated effects, most notably in the nervous andthe results obtained in the clinic, where the successful
cardiovascular system. In the latter, NO-induced cGMPisolated limb perfusion treatments were achieved with
accumulation accounts for the relaxation of vasculara single high dose administration of TNF, regression and
smooth muscle cells, responsible for the excessive va-cure of murine tumors needs repetitive daily treatments
sodilatation and hyporeactivity that are characteristicswith TNF. Since a daily administration of 15 mg/kg MB
of hypotension in shock. Other cGMP-mediated cardio-for 8 consecutive days caused toxicity as such, we de-
vascular effects include myocardial depression, causingcided to evaluate the effect of 15 mg/kg MB given every
cardiac dysfunction.other day or every third day 2 hr before TNF 1 IFNg. As
We present evidence here for MB, an inhibitor of sGCis evident from Figure 7A, pretreatment with MB did not
activation (Gruetter et al., 1981; Murad, 1986), to preventaffect the antitumor efficacy of TNF 1 IFNg at all, but
TNF-induced mortality (Figure 1), cGMP accumulationafforded considerable protection against the shock-
(Figure 3), bradycardia, and hypotension (Figure 4) ininducing effects of the antitumor treatment (Figure 7B)
mice. When used in combination with TNF and IFNg asresulting in 40%±80% survival of the cured mice (in-
an antitumor treatment, it was clear that MB successfullyjecting MB every other day or every third day, respec-
attenuated TNF-associated toxicity but not its antitumortively). A lower dose of MB (10 mg/kg), used in a sepa-
activity, thus broadening the systemic therapeutic po-rate experiment, did not cause toxicity as such when
tential of TNF (Figure 7). To further prove the involvementadministered daily and provided 80% protection against
of sGC, LY83583, another archetypal inhibitor of sGCthe TNF 1 IFNg combination, or 60% protection when
activation, was used to successfully protect micegiven every second or third day (data not shown). In
against mTNF-induced lethality (Figure 2). However,still another experiment, the TNF 1 IFNg treatment was
both MB and LY83583 have been shown to producepreceded every third day by a combination of MB and
superoxide in aqueous solutions and hence have beenthe acute phase protein a1-AGP previously reported to
postulated to exert a significant part of their effect byprotect against TNF-induced shock (Libert et al., 1994).
This protocol resulted in complete regression of the inactivating NO via complex formation. Nevertheless, in
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our experiments, total or partial inhibition of NO produc- (Alexander and Rosenberg, 1991). In 1992, a consensus
committee defined sepsis-induced hypotension by a re-tion via NOS inhibitors (Figures 1 and 5) or scaveng-
ing of NO via 2-(4-carboxyphenyl)-4,4,5,5,-tetrameth- duction in systolic blood pressure of 40 mmHg or more
from baseline (Bone et al., 1992). In our mTNF toxicityylimidazoline-1-oxyl-3-oxide (carboxy-PTIO; data not
shown) could not mimic the protective effect of MB or model in conscious unrestrained mice, we observed that
injection with TNF immediately causes a transient andLY83583, arguing against the elimination of NO to be
the principal mechanism of MB- or LY83583-mediated minor hypotensive phase, followed by a delayed fall in
blood pressure. In case of a lethal TNF challenge, severeprotection. Moreover, combining the MB treatment with
multiple injections of superoxide dismutase (SOD) or the hypotension (.40 mmHg drop) occurred in four out of
seven animals within the 10 hr observation period (Fig-cell-permeable SOD-mimetic Tempol, known to in-
crease the bioavailability of NO in vitro (ZoÈ llner et al., ure 4C). When pretreated with MB, however, this severe
delayed hypotension was never observed (Figure 4D).1997) and in vivo (Schnackenberg et al., 1998), did not
affect MB-provided protection at all (data not shown). Hence, we conclude that in nonanesthetized mice a
lethal TNF challenge is predictably accompanied by se-This indicates again that MB does not simply protect
via a superoxide-mediated mechanism. Furthermore, we vere bradycardia and, in about half the cases, by pro-
found hypotension within 10 hr after injection. Both car-actually demonstrated that MB prevents TNF-induced
cGMP production in vivo (Figure 3) and that zaprinast, a diovascular changes are without exception efficiently
prevented by a life-saving MB treatment.cGMP phospodiesterase inhibitor that increases cGMP
accumulation, abolished MB protection (data not shown). In an attempt to understand why inhibition of sGC
activation but not NO blockade could protect miceTaken together, these observations convincingly argue
for inhibition of the activation of sGC to be the mecha- against TNF lethality, we combined MB treatment with
L-NAME injection and found evidence for an indispens-nism of protection by MB against TNF-induced mor-
tality. Further evidence may come from studies using able protective role for NO in TNF toxicity, in addition
to its sGC-mediated detrimental activities. Using eNOS-knockout mice, which are currently being constructed.
When evaluating the effect of MB on TNF-induced and iNOS-deficient mice, we could confirm this protec-
tive effect. Whereas eNOS-deficient animals behavedcardiovascular changes, we found that it very efficiently
alleviated both bradycardia and hypotension. In septic just like wild-type mice, iNOS-deficient mice could not
be protected: not by MB (Figure 6C and 6D), not byshock patients, only a minor population shows reduced
cardiac output, although it has been suggested that in LY83583 (data not shown), but also not by the acute
phase protein a1-AGP previously reported to protectpatients with normal or increased cardiac output myo-
cardial depression is actually masked by the ventricular against TNF-induced shock (Libert et al., 1994) (data not
shown). Although the general assumption is for eNOS,dilation compensating for the extremely reduced ejec-
tion fraction (Parrillo et al., 1985). Later, TNF was identi- rather than iNOS, to deliver protective NO, very recently
evidence was presented for an obligatory role of inducedfied to mediate endotoxin-induced myocardial depres-
sion (Tracey et al., 1986) and to be an important NO in the cardioprotection afforded by the late phase
of ischemic preconditioning (Guo et al., 1999) and as ancardiodepressant factor in human sepsis and heart fail-
ure (Cain et al., 1998; Kubota et al., 1998). TNF by itself endogenous neuroprotectant in a mouse and rat model
of traumatic brain injury (Sinz et al., 1999). Also, in endo-depresses both animal and human cardiac function in
a dose-dependent and biphasic fashion (immediate via toxemic rats induced NO was proposed to serve as an
endogenous antiapoptotic agent in the liver (Ou et al.,spingosine [Oral et al., 1997] and delayed via NO). En-
dogenous NO evidently causes the late myocardial de- 1997), and it has been postulated that depending on the
insult induced NO can be either hepatotoxic or hepato-pression via desensitization of the myofilament to Ca21
(Finkel et al., 1992; Goldhaber et al., 1996), an effect protective (Li and Billiar, 1999). Here we present evi-
dence for a life-saving function of NO in TNF-inducedproposed to be mediated via cGMP (Hare and Colucci,
1995; Vila-Petroff et al., 1999). Leakage of TNF during toxicity, identifying iNOS as its source. Since MB pro-
tects and downmodulates cGMP in our lethality models,isolated limb perfusion was reported to cause distribu-
tive shock, in half of the patients combined with a severe we hypothesize that the protective effect of NO is inde-
pendent of cGMP accumulation. What exactly the mo-cardiogenic shock (Eggimann et al., 1995). In our mouse
experiments, mortality following TNF injection could in- lecular target is for this beneficial NO remains to be
elucidated. cGMP-independent effects of NO includevariably be predicted by a profound and sustained drop
in HR starting 1±5 hr after TNF challenge (Figure 4A). the direct scavenging of superoxide anions, the S-nitro-
sylation of proteins such as caspases (Dimmeler et al.,When pretreated with MB, a normally lethal TNF dose
causes the HR to diminish only mildly and transiently 1997) and NF-kB (Matthews et al., 1996), and the activa-
tion of cyclooxygenase (Salvemini et al., 1996). NO was(Figure 4B), an effect we also observed in case of a
nonlethal TNF injection (data not shown). also shown to interfere with apoptosis via mechanisms
other than S-nitrosylation-mediated caspase inhibition,Excessive vasodilatation and vascular hyporeactivity
with ensuing refractory hypotension have long been but the cGMP dependency of most of these effects
remains controversial (Dimmeler and Zeiher, 1997).considered hallmarks of septic shock. In endotoxic ani-
mal models, it was proven that delayed hypotension in Taken together, our results indicate that in conscious
mice TNF exerts its lethal effects via sGC activation,shock is mediated by NO exerting its vasorelaxatory
properties mainly via the activation of sGC. Also in a invariably accompanied by severe bradycardia and in
about half the cases by profound hypotension within 10hTNF-induced shock model in anesthetized dogs, NO-
dependent hypotension was shown to develop following hr of observation. Pretreatment with MB can efficiently
prevent TNF-induced cGMP accumulation, bradycardia,sublethal TNF injection (Kilbourn et al., 1990). In most
phase I clinical TNF trials, hypotension reliably occurred hypotension, and mortality but does not interfere with
antitumor activities, thus broadening the therapeutic po-and a severe drop of systolic blood pressure (.40
mmHg) was observed in 25% of the evaluable patients tential of systemic TNF as an anticancer treatment. In
NO and sGC in TNF Toxicity in Mice
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MAP and HR Measurementsaddition, iNOS-derived NO exerts protective effects
It has been documented using eNOS-deficient mice that mere anes-against TNF toxicity, arguing against the therapeutic use
thesia influences NO-mediated blood pressure changes in mice (Maof iNOS-selective inhibitors in TNF-induced or -medi-
et al., 1996). Hence, we chose to measure blood pressure in con-ated pathologies such as septic shock, hepatotoxicity,
scious mice. In a computerized tail±cuff method, however, very early
inflammatory bowel diseases, or myocardial ischemia- after TNF challenge, pulse amplitude was reduced to values insuffi-
reperfusion. cient to use this technique, which left us with the method of perma-
nent catheterization in mice. Mice were instrumented with catheters
as described in detail previously (Janssen et al., 2000). In short,
Experimental Procedures under ketamine (100 mg/kg i.m.) and xylazine (5 mg/kg s.c.) anesthe-
sia, a heat-stretched piece of polyethylene (PE25) tubing (OD/ID
Cytokines, Cell Lines, and Reagents 0.15/0.1 mm at the tip) was inserted (1.5 cm) into the right femoral
Recombinant hTNF, mTNF, and mIFNg were produced in Esche- artery and subcutaneously guided to the neck of the mouse. Here
richia coli and purified to homogeneity in our laboratory. The endo- the catheter was fixed, extended, filled with heparinized saline (10
toxin content was ,0.02 ng/mg, as assessed by a chromogenic U/ml), and plugged. A venous catheter (silastic OD/ID 0.25/0.12 mm)
Limulus amoebocyte lysate assay (Coatest; Kabivitrium, Stockholm, was inserted into the right jugular vein and similarly guided and
Sweden). Live BCG organisms were provided by the Institut Pasteur extended in the neck to allow i.v. injections of reagents (200 ml of
du Brabant (Brussels, Belgium), and recombinant mIL-12 was gener- glucose or MB 2 hr before mTNF or PBS challenge) without dis-
ously provided by Dr. M. Gately (Hoffmann-La Roche, Nutley, NJ). turbing hemodynamics. After surgery, animals received i.p. 2 ml of
Murine LLC clone H61 and the B16BL6 melanoma subline were gifts a Ringer's solution to improve recovery as well as buprenorphine
from Dr. M. Mareel (University Hospital, Ghent, Belgium) by courtesy (2 mg/kg s.c.) as analgesic agent. The mice were kept at 308C until
of Dr. G. Vaes and Dr. I. Fidler, respectively. Tumor cells were cul- fully recovered from the anesthesia and housed individually. Experi-
tured in DMEM supplemented with 10% FCS, 50 U/ml penicillin ments were performed 3±6 days after surgery. On the day of the
G, 50 mg/ml streptomycin sulfate, and 2 mM L-glutamine. Before experiment, the arterial catheter was connected to a low-volume
injection, cells were washed twice in PBS. NOS inhibitors L-NAME, pressure transducer (micro-switch, model 156PC 156WL, Honeywell
L-NMMA, and L-NIO were purchased at Novabiochem and injected Inc., Amsterdam, the Netherlands) to record blood pressure. MAP
i.v. at a dose of 100 mg/kg unless stated otherwise. MB (Sterop and HR were measured continuously throughout the study. The
Pharmacobel, Belgium) was purchased in glucose solution suitable preparation was allowed to stabilize for 50±90 min before the start
for i.v. injection and was administered at a dose of 15 mg/kg unless of the experiment.
mentioned otherwise. Glucose (Sterop Pharmacobel, Belgium) was
used as a control. LY83583 (Biomol Research) was injected i.v. at
NOx2 Measurement2.5 mg/kg in 25% DMSO. Zaprinast (Novabiochem) was adminis-
Blood was collected via cardiac puncture, allowed to clot at 378C,tered i.v. at 30 mg/kg per injection. Injection solutions were diluted in
and subsequently centrifuged to obtain serum. Sera were half di-endotoxin-free PBS, and, unless stated otherwise, injection volumes
luted with 5.109 CFU/ml Pseudomonas oleovorans suspension (re-were 200 ml.
ducing nitrate to nitrite) and incubated at 378C for 2 hr. After removal
of the bacteria by centrifugation, the supernatant was one-third
diluted with Griess reagent (Green et al., 1982) and serum proteinsMouse Models
were precipitated by addition of 10% TCA. The absorbance of theFemale C57Bl/6 mice (Charles River, Sulzfeld, Germany), eNOS-
supernatant was measured at 540 nm. Total NOx2 concentrationsdeficient mice (Huang et al., 1995), or iNOS-deficient mice (Laubach
were calculated based on a nitrate standard curve.et al., 1995) (Jackson Laboratories) were used at the age of 7±12
weeks at the beginning of the experiment. The animals were housed
in temperature-controlled, air-conditioned facilities with 12 hr dark/ Antitumor Treatment
light cycles and food and water ad libitum. All experiments were C57Bl/6 mice were inoculated s.c. with 6.105 B16BL6 melanoma
approved by and performed according to the guidelines of the ani- cells on day 0. Paralesional treatment with 10 mg mTNF and 5000
mal ethics committee from the Universities of Ghent, Belgium, and IU mIFNg started on day 10, when the tumor inoculum formed a
Maastricht, The Netherlands. Four different TNF lethality models palpable tumor. Tumor-bearing mice were thus treated for 8 consec-
were used. In model I, a lethal dose of mTNF is injected i.v. in utive days. Tumor size was assessed every 2±3 days and expressed
healthy, nonsensitized mice. The sensitization models II, III, and IV as 0.4 3 a2 3 b, with a being the smaller and b the larger diameter
were performed as described in detail before (Cauwels et al., 1995, of the tumor. Deaths were monitored daily. When mentioned, MB
1996). Briefly, in model II mice bearing an i.m. LLCH61 tumor with was administered i.v. daily, every second day, or every third day,
a diameter of about 15 mm are challenged with 20 mg hTNF, while each time 2 hr before the TNF 1 IFNg treatment.
in model III mice are sensitized by a BCG infection 2 weeks before
being challenged by a 10±15 mg hTNF injection. Model IV consists
Statisticsof a daily i.p. treatment with 1 mg rmIL-12 during 5 consecutive
Significance of change in cGMP or NOx2 levels was examined usingdays, followed after a 2 day interval by a lethal hTNF challenge of
a one-way ANOVA Bonferroni test (with comparison of all pairs).5±10 mg. All TNF injections shown are i.v. (200 ml, diluted in endo-
For survival studies in Figure 7, statistical significance was evaluatedtoxin-free PBS) and 100% lethal. The LD100 was determined with
using a logrank test.exactly the same lot of TNF and mice before the start of each
individual experiment. Lethality is generally scored up to 7 days
after TNF challenge.
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